ADHD용 디지털 치료제 시장 예측(-2034년) - 제품 유형, 연령층, 제공 플랫폼, 비즈니스 모델, 용도, 최종사용자 및 지역별 분석

According to Stratistics MRC, the Global Digital Therapeutics for ADHD Market is accounted for $1.5 billion in 2026 and is expected to reach $6.8 billion by 2034 growing at a CAGR of 20.7% during the forecast period. Digital therapeutics for ADHD are evidence-based software applications delivered via smartphones, tablets, personal computers, and wearable devices that provide therapeutic interventions for attention deficit hyperactivity disorder through mechanisms including cognitive training, behavioral therapy, neurofeedback, and attention regulation exercises delivered in gamified and interactive formats. These prescription and non-prescription digital interventions are designed to improve attention capacity, impulse control, executive function, and behavioral self-regulation through repeated engagement with scientifically validated therapeutic protocols, often prescribed in conjunction with pharmacotherapy or as standalone treatment alternatives for patients seeking non-pharmacological ADHD management options.

Market Dynamics:

Driver:

ADHD Medication Access Barriers

Access barriers to traditional ADHD medications, including stimulant shortages, prescription regulatory restrictions, side effect concerns, and patient preference for non-pharmacological treatment options, are driving significant demand for digital therapeutics as viable alternative or complementary treatment approaches for attention deficit hyperactivity disorder. The increasing diagnosis rates of ADHD across pediatric, adolescent, and adult populations have created substantial treatment demand that conventional medication supply chains cannot fully satisfy, while patient concerns regarding stimulant side effects have motivated interest in FDA-cleared digital treatment options. Healthcare provider recognition of digital therapeutics as evidence-based interventions is expanding prescription and recommendation patterns.

Restraint:

Reimbursement Coverage Limitations

Limited reimbursement coverage and payer acceptance of digital therapeutics for ADHD represent significant market restraints, as many health insurance plans and government healthcare programs have not established adequate coverage policies for prescription digital therapeutics, creating out-of-pocket cost barriers that restrict patient access and limit market expansion. Reimbursement approval processes require extensive clinical evidence and cost-effectiveness data that digital therapeutic companies must generate through expensive clinical trials, while healthcare provider prescribing patterns remain cautious without established reimbursement pathways. The fragmented US payer landscape and diverse international reimbursement systems create market access complexity for digital therapeutic companies.

Opportunity:

Pediatric Mental Health Integration

Integration with pediatric mental health services presents a significant market opportunity for ADHD digital therapeutics, as the established demand for pediatric ADHD treatment creates ready adoption pathways through children's hospitals, behavioral health centers, school-based health services, and pediatric mental health specialist networks. Digital therapeutics deployed in clinical settings enable continuous therapeutic engagement between clinical appointments while providing objective performance data for treatment monitoring and adjustment. The growing emphasis on pediatric mental health infrastructure investment, including school-based mental health services and telehealth platforms, is expanding market access points for ADHD digital therapeutic products.

Threat:

Competition from Wellness Apps

Competition from free or low-cost wellness applications offering attention training and cognitive exercises without clinical evidence requirements constitutes a persistent market threat, as consumers often cannot distinguish between clinically validated prescription digital therapeutics and general wellness apps that lack scientific substantiation for ADHD-specific therapeutic claims. The proliferation of attention-focused applications in app stores creates consumer confusion and price pressure on evidence-based digital therapeutics, while limited healthcare provider awareness of product differentiation between wellness apps and regulated digital therapeutics restricts prescription adoption. Regulatory enforcement against unsubstantiated clinical claims in wellness apps remains inconsistent across jurisdictions.

Covid-19 Impact:

COVID-19 significantly accelerated the digital therapeutics for ADHD market through widespread adoption of telehealth services, increased remote monitoring capabilities, and expanded recognition of digital interventions as essential healthcare tools during pandemic-related healthcare access restrictions. The pandemic increased ADHD diagnosis and treatment demand as remote work, online schooling, and pandemic-related stress exacerbated attention and executive function challenges across populations. Post-pandemic structural impacts include permanent acceptance of digital therapeutics in healthcare delivery, expanded insurance coverage recognition, and integration of digital mental health tools into mainstream ADHD treatment protocols.

The prescription digital therapeutics segment is expected to be the largest during the forecast period

The prescription digital therapeutics segment is expected to account for the largest market share during the forecast period, due to the FDA clearance of prescription digital therapeutics for ADHD treatment generating clinical credibility, healthcare provider confidence, and patient trust in regulated digital interventions with demonstrated safety and efficacy evidence. Prescription digital therapeutics benefit from established physician prescribing patterns that integrate digital interventions with conventional ADHD treatment protocols, while reimbursement coverage is more likely for FDA-cleared therapeutic products compared to unregulated wellness applications. The prescription requirement creates clinical oversight and patient engagement pathways that optimize treatment outcomes and support market growth.

The mobile application-based therapeutics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the mobile application-based therapeutics segment is predicted to witness the highest growth rate, driven by the ubiquitous availability of smartphones and the convenience, accessibility, and engagement advantages of mobile-delivered therapeutic interventions that support daily ADHD management in real-world contexts. Mobile application therapeutics enable continuous patient engagement through push notifications, progress tracking, and gamified interfaces that increase treatment adherence compared to clinic-based or web-based alternatives. The scalability of mobile application distribution through app stores and digital prescription systems enables rapid market expansion and reduced incremental costs per patient.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the highest diagnosed ADHD prevalence rates, established regulatory framework for prescription digital therapeutics through the FDA, favorable reimbursement environment for digital health interventions, and concentration of digital therapeutic companies including Akili, Inc. and Pear Therapeutics, Inc. The United States leads regional demand through strong clinical adoption of digital therapeutics, healthcare innovation culture, and substantial investment in digital mental health solutions from venture capital and established healthcare companies. Federal recognition of digital therapeutics as reimbursable health interventions is expanding market access.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to increasing ADHD diagnosis awareness, growing mental health acceptance across Asian societies, rising healthcare spending, and expanding digital health infrastructure in China, Japan, South Korea, and Australia. China's digital health policy emphasis and growing recognition of pediatric mental health needs are driving institutional interest in ADHD digital therapeutics, while telemedicine expansion increases access to specialized ADHD diagnosis and treatment in underserved regions. Regional development of culturally adapted digital therapeutics and local language applications is supporting market penetration.

Key players in the market

Some of the key players in Digital Therapeutics for ADHD Market include Akili, Inc., Pear Therapeutics, Inc., Big Health, Inc., Limbix Health, Inc., EndeavorRx, Monument Therapeutics, Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Medtronic plc, Omada Health, Inc., DarioHealth Corp., Click Therapeutics, Inc., Woebot Health, Headspace Health, Better Therapeutics, Inc., X2AI, Inc., and Cognoa, Inc.

Key Developments:

In August 2026, Akili, Inc. received expanded FDA clearance for its pediatric ADHD digital therapeutic, enabling broader clinical adoption and improving access to digital treatment options for children with ADHD.

In July 2026, Pear Therapeutics, Inc. announced positive clinical trial results for its adult ADHD digital therapeutic, demonstrating significant symptom improvement and strengthening evidence supporting digital interventions for adult ADHD management.

In June 2026, Click Therapeutics, Inc. launched a new mobile-based ADHD therapeutic targeting executive function deficits with gamified cognitive training modules, supporting personalized treatment and improving engagement among patients.

Product Types Covered:

• Prescription Digital Therapeutics
• Non-Prescription Digital Therapeutics
• Software-Based Therapeutic Programs
• Video Game-Based Therapeutics
• Mobile Application-Based Therapeutics
• Web-Based Therapeutic Platforms

Age Groups Covered:

• Children
• Adolescents
• Adults
• Older Adults

Delivery Platforms Covered:

• Smartphones
• Tablets
• Personal Computers
• Wearable Devices
• Web-Based Platforms

Business Models Covered:

• Subscription-Based
• One-Time Purchase
• Reimbursement-Based
• Employer-Sponsored
• Healthcare Provider-Sponsored

Applications Covered:

• Attention Training
• Impulse Control
• Cognitive Function Improvement
• Behavioral Management
• Medication Adherence Support
• Remote Patient Monitoring
• Other Applications

End Users Covered:

• Hospitals and Clinics
• Behavioral Health Centers
• Academic and Research Institutions
• Homecare Settings
• Individual Users
• Other End Users

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Digital Therapeutics for ADHD Market, By Product Type

• 5.1 Prescription Digital Therapeutics
• 5.2 Non-Prescription Digital Therapeutics
• 5.3 Software-Based Therapeutic Programs
• 5.4 Video Game-Based Therapeutics
• 5.5 Mobile Application-Based Therapeutics
• 5.6 Web-Based Therapeutic Platforms

6 Global Digital Therapeutics for ADHD Market, By Age Group

• 6.1 Children
• 6.2 Adolescents
• 6.3 Adults
• 6.4 Older Adults

7 Global Digital Therapeutics for ADHD Market, By Delivery Platform

• 7.1 Smartphones
• 7.2 Tablets
• 7.3 Personal Computers
• 7.4 Wearable Devices
• 7.5 Web-Based Platforms

8 Global Digital Therapeutics for ADHD Market, By Business Model

• 8.1 Subscription-Based
• 8.2 One-Time Purchase
• 8.3 Reimbursement-Based
• 8.4 Employer-Sponsored
• 8.5 Healthcare Provider-Sponsored

9 Global Digital Therapeutics for ADHD Market, By Application

• 9.1 Attention Training
• 9.2 Impulse Control
• 9.3 Cognitive Function Improvement
• 9.4 Behavioral Management
• 9.5 Medication Adherence Support
• 9.6 Remote Patient Monitoring
• 9.7 Other Applications

10 Global Digital Therapeutics for ADHD Market, By End User

• 10.1 Hospitals and Clinics
• 10.2 Behavioral Health Centers
• 10.3 Academic and Research Institutions
• 10.4 Homecare Settings
• 10.5 Individual Users
• 10.6 Other End Users

11 Global Digital Therapeutics for ADHD Market, By Geography

• 11.1 North America
  • 11.1.1 United States
  • 11.1.2 Canada
  • 11.1.3 Mexico
• 11.2 Europe
  • 11.2.1 United Kingdom
  • 11.2.2 Germany
  • 11.2.3 France
  • 11.2.4 Italy
  • 11.2.5 Spain
  • 11.2.6 Netherlands
  • 11.2.7 Belgium
  • 11.2.8 Sweden
  • 11.2.9 Switzerland
  • 11.2.10 Poland
  • 11.2.11 Rest of Europe
• 11.3 Asia Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 South Korea
  • 11.3.5 Australia
  • 11.3.6 Indonesia
  • 11.3.7 Thailand
  • 11.3.8 Malaysia
  • 11.3.9 Singapore
  • 11.3.10 Vietnam
  • 11.3.11 Rest of Asia Pacific
• 11.4 South America
  • 11.4.1 Brazil
  • 11.4.2 Argentina
  • 11.4.3 Colombia
  • 11.4.4 Chile
  • 11.4.5 Peru
  • 11.4.6 Rest of South America
• 11.5 Rest of the World (RoW)
  • 11.5.1 Middle East
    • 11.5.1.1 Saudi Arabia
    • 11.5.1.2 United Arab Emirates
    • 11.5.1.3 Qatar
    • 11.5.1.4 Israel
    • 11.5.1.5 Rest of Middle East
  • 11.5.2 Africa
    • 11.5.2.1 South Africa
    • 11.5.2.2 Egypt
    • 11.5.2.3 Morocco
    • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

• 12.1 Industry Value Network and Supply Chain Assessment
• 12.2 White-Space and Opportunity Mapping
• 12.3 Product Evolution and Market Life Cycle Analysis
• 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

• 13.1 Mergers and Acquisitions
• 13.2 Partnerships, Alliances, and Joint Ventures
• 13.3 New Product Launches and Certifications
• 13.4 Capacity Expansion and Investments
• 13.5 Other Strategic Initiatives

14 Company Profiles

• 14.1 Akili, Inc.
• 14.2 Pear Therapeutics, Inc.
• 14.3 Big Health, Inc.
• 14.4 Limbix Health, Inc.
• 14.5 EndeavorRx
• 14.6 Monument Therapeutics
• 14.7 Otsuka Pharmaceutical Co., Ltd.
• 14.8 Takeda Pharmaceutical Company Limited
• 14.9 Medtronic plc
• 14.10 Omada Health, Inc.
• 14.11 DarioHealth Corp.
• 14.12 Click Therapeutics, Inc.
• 14.13 Woebot Health
• 14.14 Headspace Health
• 14.15 Better Therapeutics, Inc.
• 14.16 X2AI, Inc.
• 14.17 Cognoa, Inc.